Giansun Precision Technology Group
001400
Heilongjiang Tianyouwei Electronics
603202
Joy Kie Corporation
300994
4
Kingchem
301509
5
Hunan Er-kang Pharmaceutical
300267
CN Stock MarketDetailed Quotes
603205 Jianerkang Medical
- 43.75
- +3.98+10.01%
Not Open Apr 24 15:00 CST
5.25BMarket Cap42.31P/E (TTM)
43.75High38.76Low157.85KlotVolume40.32Open39.77Pre Close656.16MTurnover53.69%Turnover Ratio43.66P/E (Static)120.00MShares96.2152wk High3.62P/B1.29BFloat Cap30.0352wk Low43.75Limit Up29.40MShs Float96.21Historical High35.79Limit Down12.55%Amplitude30.03Historical Low--Dividend TTM41.57Avg Price72.73KlotAsk--Div YieldTTM100Lot Size78.52KlotBid
Jianerkang Medical Key Stats
All
YOY
| (Q3)Mar 31, 2025 | (FY)Dec 31, 2024 | (Q9)Sep 30, 2024 | (Q6)Jun 30, 2024 | (Q3)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q9)Sep 30, 2023 | (Q6)Jun 30, 2023 | (Q3)Mar 31, 2023 | (FY)Dec 31, 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total operating revenue | 13.69%240.89M | 1.18%1.05B | 10.07%782.94M | 5.97%504.53M | 0.48%211.89M | -5.46%1.03B | -6.45%711.33M | -7.68%476.12M | 210.88M | 39.79%1.09B |
| Operating revenue | 13.69%240.89M | 1.18%1.05B | 10.07%782.94M | 5.97%504.53M | 0.48%211.89M | -5.46%1.03B | -6.45%711.33M | -7.68%476.12M | --210.88M | 39.79%1.09B |
| Other operating revenue | ---- | 187.75%4.02M | ---- | 433.41%3.19M | ---- | -49.55%1.4M | ---- | --598.85K | ---- | 47.32%2.77M |
| Total operating cost | 11.29%207.23M | 2.36%905.35M | 11.63%677.99M | 7.44%434.77M | 186.21M | -1.91%884.5M | 607.36M | -6.01%404.68M | 30.28%901.69M | |
| Operating cost | 9.93%180.35M | 0.88%804.55M | 10.35%603.79M | 5.87%390.48M | --164.06M | -3.81%797.57M | --547.13M | -8.31%368.83M | ---- | 38.79%829.19M |
| Operating tax surcharges | -6.86%2.17M | 22.01%9.62M | 21.30%6.62M | 5.92%4.33M | --2.33M | -13.23%7.89M | --5.46M | 11.54%4.09M | ---- | 41.45%9.09M |
| Operating expense | 0.96%6.11M | 2.82%26.74M | 8.87%19.69M | 9.57%13.41M | --6.05M | 0.15%26.01M | --18.09M | 25.17%12.24M | ---- | 31.40%25.97M |
| Administration expense | 41.54%11.83M | 28.07%36.66M | 8.07%23.59M | 5.77%15.72M | --8.36M | -8.71%28.63M | --21.83M | 2.24%14.86M | ---- | -1.67%31.36M |
| Financial expense | -3.76%-2.71M | -6.38%-12.95M | 47.15%-5.83M | 30.70%-8.63M | ---2.62M | 58.32%-12.18M | ---11.04M | 22.13%-12.45M | ---- | -464.66%-29.21M |
| -Interest expense (Financial expense) | ---- | -99.22%5.1K | ---- | ---- | ---- | -60.77%650.76K | --581.1K | -18.73%420.1K | ---- | 129.74%1.66M |
| -Interest Income (Financial expense) | -46.64%-2.82M | -57.76%-6.87M | -146.00%-6.3M | -229.23%-4.49M | ---1.92M | -69.73%-4.35M | ---2.56M | -2,949.52%-1.36M | ---- | -2,572.14%-2.57M |
| Research and development | 18.11%9.49M | 11.30%40.72M | 16.39%30.14M | 13.71%19.46M | --8.04M | 3.65%36.59M | --25.89M | 5.00%17.11M | ---- | 23.26%35.3M |
| Credit Impairment Loss | -95.61%181.38K | 108.09%484.89K | 161.31%3.11M | 120.29%1.48M | --4.14M | 58.73%-6M | ---5.07M | 15.28%-7.32M | ---- | -375.52%-14.53M |
| Asset Impairment Loss | 5.69%-2.28M | -55.01%-7.31M | 13.25%-4.88M | 3.92%-4.04M | ---2.42M | 13.03%-4.72M | ---5.63M | -32.80%-4.21M | ---- | -123.39%-5.42M |
| Other net revenue | -138.06%-948.84K | 88.87%-1.57M | 108.14%1.22M | 95.98%-675.7K | 2.49M | 7.92%-14.12M | -15.05M | -66.96%-16.81M | 0 | -181.93%-15.34M |
| Fair value change income | --130.12K | ---- | --75.62K | ---- | ---- | ---488.6K | ---- | ---- | ---- | ---- |
| Invest income | ---- | 104.60%744.42K | 98.80%-195.4K | 98.80%-195.4K | ---195.4K | -15,829.52%-16.19M | ---16.23M | -35,606.37%-16.23M | ---- | -70.56%102.93K |
| Asset deal income | ---- | 1,375.73%433.86K | 660.40%212.44K | --212.44K | ---- | 100.97%29.4K | --27.94K | ---- | ---- | -2,388.85%-3.02M |
| Other revenue | 5.15%1.02M | -69.22%4.07M | -75.47%2.91M | -82.97%1.86M | --967.99K | 75.67%13.24M | --11.85M | 130.57%10.95M | ---- | -51.03%7.54M |
| Operating profit | 16.13%32.72M | 2.92%138.85M | 19.39%106.17M | 26.43%69.08M | 28.17M | -23.44%134.9M | 88.93M | -27.26%54.63M | 62.23%176.2M | |
| Add:Non operating Income | -17.64%43.73K | -92.83%567.08K | -96.15%282.86K | -96.95%222.65K | --53.1K | 338.93%7.9M | --7.35M | 8,499.48%7.3M | ---- | -95.66%1.8M |
| Less:Non operating expense | 0.00%4K | 841.02%1.72M | 38.14%56.63K | 78.09%37.65K | --4K | 5.11%182.62K | --41K | -83.02%21.14K | ---- | -61.23%173.74K |
| Total profit | 16.07%32.75M | -3.46%137.69M | 10.55%106.39M | 11.87%69.26M | -1.55%28.22M | -19.80%142.62M | -17.20%96.24M | -17.52%61.91M | 28.66M | 18.84%177.83M |
| Less:Income tax cost | 21.00%3.95M | -8.40%17.48M | 0.77%12.94M | -4.51%8.32M | --3.26M | -6.90%19.08M | --12.84M | -11.88%8.71M | ---- | 13.83%20.49M |
| Net profit | 15.42%28.81M | -2.69%120.22M | 12.06%93.46M | 14.55%60.94M | 3.49%24.96M | -21.48%123.55M | -17.08%83.4M | -18.38%53.2M | 24.12M | 19.53%157.34M |
| Net profit from continuing operation | 15.42%28.81M | -2.69%120.22M | 12.06%93.46M | 14.55%60.94M | --24.96M | -21.48%123.55M | --83.4M | --53.2M | ---- | 19.53%157.34M |
| Net profit of parent company owners | 15.42%28.81M | -2.69%120.22M | 12.06%93.46M | 14.55%60.94M | 3.49%24.96M | -21.48%123.55M | -17.08%83.4M | -18.38%53.2M | --24.12M | 19.53%157.34M |
| Earning per share | ||||||||||
| Basic earning per share | -14.29%0.24 | -7.30%1.27 | 12.05%1.0384 | 14.55%0.6771 | --0.28 | -21.63%1.37 | --0.9267 | -17.90%0.5911 | ---- | 19.54%1.7482 |
| Diluted earning per share | -14.29%0.24 | -7.30%1.27 | ---- | 14.55%0.6771 | --0.28 | -21.63%1.37 | ---- | -17.90%0.5911 | ---- | 19.54%1.7482 |
| Other composite income | -632.88 | -1.82 | ||||||||
| Other composite income of parent company owners | ---632.88 | ---1.82 | ---- | ---- | ---- | ---- | ---- | ---- | ---- | ---- |
| Total composite income | 15.42%28.8M | -2.69%120.22M | 12.06%93.46M | 14.55%60.94M | 24.96M | -21.48%123.55M | 83.4M | -18.38%53.2M | 19.53%157.34M | |
| Total composite income of parent company owners | 15.42%28.8M | -2.69%120.22M | 12.06%93.46M | 14.55%60.94M | --24.96M | -21.48%123.55M | --83.4M | --53.2M | ---- | 19.53%157.34M |
| Currency Unit | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY | CNY |
| Accounting Standards | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) | CAS (2007) |
| Audit Opinions | -- | Unqualified opinion | -- | -- | -- | Unqualified opinion | -- | -- | -- | Unqualified opinion |
| Auditor | -- | Tianheng Certified Public Accountants (Special General Partnership) | -- | -- | -- | Tianheng Certified Public Accountants (Special General Partnership) | -- | -- | -- | Tianheng Certified Public Accountants (Special General Partnership) |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.